查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032603

腎上腺素自動注射器市場報告：按劑量、應用、最終用戶和地區分類（2026-2034 年）

Epinephrine Autoinjector Market Report by Dosage, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球腎上腺素自動注射器市場規模達28億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到55億美元，2026年至2034年的複合年成長率為7.49%。過敏人群數量的增加、自我用藥需求的成長以及智慧腎上腺素自動注射器的推出是推動市場成長的主要因素。

全球腎上腺素自動注射器市場趨勢：

過敏反應嚴重

過敏反應（可導致呼吸急促、水腫和低血壓）發生率的上升是推動市場成長的主要因素。此外，關節炎、氣喘、癌症和慢性阻塞性肺病（COPD）的盛行率急劇上升也促進了市場成長。例如，根據氣喘與過敏基金會的報告，約有10.8%的成年女性患有氣喘，而成年男性盛行率為6.5%。氣喘是兒童主要的慢性疾病之一。目前，約有450萬18歲以下的兒童氣喘。 7.7%的美國人患有氣喘，其中約有2,490萬人，包括2,020萬成年人和460萬兒童。同樣，據報導，印度慢性阻塞性肺病（COPD）病例佔全球的比例從1990年的3.3%（2810萬例）上升到2016年的4.4%（5530萬例）。此外，全球老年人口的不斷成長，尤其是易患過敏症的老年人口，也推動了市場成長。例如，目前美國居住6,200萬65歲及以上的老年人，佔總人口的18%。預計到2054年，這數字將達到8,400萬，佔總人口的23%。人口老化的顯著成長，以及由叮咬、昆蟲叮咬、藥物和其他環境刺激物引起的嚴重過敏反應病例的增加，預計將在未來幾年內提​​升腎上腺素自動注射器的市場佔有率。

新產品發布量增加

市場主要參與者不斷加強策略活動力度，包括推出新產品、併購、近期發展、合資企業、聯盟和夥伴關係，這些都為整個市場帶來了光明的前景。例如，2022年11月，Catalent宣布計畫為比利時Adamis Pharmaceuticals生產新一批SYMJEPI。 SYMJEPI於2023年第一季重新上市並商業化。此外，藥品監管機構正在加快藥品核准流程，這為整個市場創造了巨大的成長機會。例如，2022年8月，Anfaster Pharmaceuticals宣布其單劑量預填充式注射器的新藥認證申請已獲得美國食品藥物管理局（FDA）的核准。此外，為加快藥物研發步伐併購活動也對腎上腺素自動注射器市場的前景產生了正面影響。例如，2022年2月，賽諾菲收購了Amnix公司。此次收購使其獲得了Amnix公司的Pro-XTEN、XPAT和XPAC技術，用於給藥新一代條件活化生技藥品。預計此類創新將在預測期內推動市場成長。

提高意識和改善獲取途徑

人們對過敏症的認知不斷提高，以及醫療保健服務的可近性不斷改善，正在擴大市場，尤其是在過敏症管理日益重要的發展中地區。此外，許多國家的監管機構正致力於在學校和其他公共場所推廣使用腎上腺素自動注射器，這對整體市場產生了積極影響。例如，2023年6月，英國藥品和保健產品監管局（MHRA）在過敏意識倡導者的支持下發起了一項安全宣傳活動，旨在提高人們對過敏性休克的認知，並提供腎上腺素自動注射器的使用建議。此外，多家私人製藥公司正努力降低腎上腺素自動注射器的價格，以服務低收入族群。例如，全球學名藥和專科製藥公司邁蘭（Mylan NV）在其「自動注射器病患支援計畫」下免費提供Epipen（腎上腺素注射液，USP）。該計劃的申請條件包括：必須是合法居住者、收入符合限制，且沒有處方藥或品牌藥的保險。合格的申請人可以免費獲得藥物。政府和私人企業的這些舉措預計將在未來幾年推動腎上腺素自動注射器市場的成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球腎上腺素自動注射器市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場細分：依劑量

  • 0.15毫克腎上腺素自動注射器
  • 0.3毫克腎上腺素自動注射器
  • 0.5毫克腎上腺素自動注射器

第7章 市場區隔：依應用領域分類

  • 6歲以下
  • 6-12歲
  • 12歲以上

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進、抑制與機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Adamis Pharmaceuticals Corporation
    • Amneal Pharmaceuticals Inc.
    • Antares Pharma Inc
    • Bausch Health
    • Kaleo Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: SR112026A7369

The global epinephrine autoinjector market size reached USD 2.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.49% during 2026-2034. The increasing number of individuals with allergies, rising need for self-administrating medicines, and the launch of smart epinephrine autoinjector represent some of the key factors driving the market.

GLOBAL EPINEPHRINE AUTOINJECTOR MARKET ANALYSIS:

  • Major Market Drivers: The increasing number of individuals with allergies and allergic reactions and the rising need for self-administrating medicines are primarily driving the growth of the market. Moreover, the growing aging population, which is more prone to develop allergic reactions, is influencing the market positively.
  • Key Market Drivers: The introduction of smart epinephrine autoinjectors that are integrated with advanced technologies, including Bluetooth connectivity, sensors, and machine learning, to make them more convenient, user-friendly, and effective is acting as a significant growth-inducing factor for the market.
  • Competitive Landscape: Some of the leading epinephrine autoinjector market companies operating in the global market include Adamis Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Antares Pharma Inc., Bausch Health, Kaleo Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc., among others.
  • Geographical Landscape: According to the report, North America was the largest market for epinephrine autoinjectors. Some of the factors driving the North America epinephrine autoinjector market included the rising prevalence of allergies, increasing awareness about anaphylaxis, and the availability of cost-effective generic versions of autoinjectors.
  • Challenges and Opportunities: Challenges for the global epinephrine autoinjector market include regulatory hurdles and pricing pressures, while opportunities lie in expanding awareness about severe allergies and increasing adoption of these devices in both medical and non-medical settings.

GLOBAL EPINEPHRINE AUTOINJECTOR MARKET TRENDS:

Increasing Prevalence of Severe Allergic Reactions

The rising incidences of allergic reactions, which can cause difficulty in breathing, swelling, and low blood pressure, are primarily driving the growth of the market. Additionally, the surging prevalence of arthritis, asthma, cancer, and chronic obstructive pulmonary disease (COPD) are also contributing to the market growth. For instance, according to a report by the Asthma and Allergy Foundation of America, around 10.8% of female adults have asthma, compared to 6.5% of male adults. It is a leading chronic disease in children. Currently, there are about 4.5 million children under the age of 18 with asthma. 7.7% of Americans have asthma. Of these roughly 24.9 million, 20.2 million are adults, and 4.6 million are children. Similarly, the global burden of COPD in India reported an increase from 3.3% (28.1 million cases) in 1990 to 4.4% (55.3 million cases) in 2016. Besides this, the escalating geriatric population across the world, which is more prone to developing allergies, is also contributing to the growth of the market. For instance, there are currently roughly 62 million adults ages 65 and older living in the U.S., accounting for 18% of the population. By 2054, 84 million adults aged 65 and older will make up an estimated 23% of the population. Such a significant rise in the aging population and the rising cases of severe allergic reactions caused by stings, bug bites, drugs, or any other environmental irritant are anticipated to propel the epinephrine autoinjector market share in the coming years.

Growing Product Launches

The increasing number of new product launches and strategic activities, such as mergers/acquisitions, recent developments, joint ventures, collaborations, and partnerships by major players in the market, is creating a positive outlook for the overall market. For instance, in November 2022, Catalent announced its plans to manufacture a new batch of SYMJEPI for Adamis Pharmaceuticals Co. in Belgium. The relaunch and commercial availability of SYMJEPI took place in the first quarter of 2023. Furthermore, the medicine regulatory authorities are also expediating the approval process of drugs and medicines which is offering lucrative growth opportunities to the overall market. For example, in August 2022, Amphastar Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved the company's New Drug Application for an Epinephrine Single Dose Pre-Filled Syringe. Besides this, the rise in merger and acquisition activities to propel the pace of drug development is positively impacting the epinephrine autoinjector market outlook. For instance, in February 2022, Sanofi acquired Amunix, which gives access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next-generation Conditionally Activated Biologics. Such innovations are projected to bolster the growth of the market over the forecasted period.

Rising Awareness and Accessibility

Heightened awareness about allergies and improved accessibility to healthcare services are expanding the market, particularly in developing regions where allergy management is gaining importance. Furthermore, governing agencies of numerous countries are undertaking initiatives to promote the use of epinephrine autoinjectors in schools and other public spaces, which is creating a positive impact on the overall market. For instance, in June 2023, the MHRA, with the support of allergy awareness advocates, launched a safety campaign to raise awareness of anaphylaxis and provide advice on the use of adrenaline autoinjectors. Additionally, various private pharmaceutical companies are also taking initiatives to provide epinephrine autoinjectors at reasonably low prices to cater to the lower income groups. For instance, Mylan N.V., a global generic and specialty pharmaceuticals company, offers EpiPen (epinephrine injection, USP) for free under the Autoinjector Patient Assistance Program. The requirements for this include legal residency status, income limits, and lack of insurance coverage for prescriptions or for brand-name prescriptions. Patients who apply and are found eligible may receive medication free of charge. Such initiatives by government and private market players are projected to propel the epinephrine autoinjector market growth in the coming years.

GLOBAL EPINEPHRINE AUTOINJECTOR INDUSTRY SEGMENTATION:

Breakup by Dosage:

  • 0.15mg Epinephrine Autoinjector
  • 0.3mg Epinephrine Autoinjector
  • 0.5mg Epinephrine Autoinjector

0.3mg epinephrine autoinjector represented the largest segment

Several social and psychological factors contribute significantly to the prevalence of anaphylaxis among adolescents and adults. Healthcare professionals recommend the use of epinephrine auto-injectors at a safe dosage, typically 0.3 mg, for patients aged 12 years and older. Various guidelines, such as the RCUK 2008/2021 in the UK, EAACI 2014/2021 in Europe, and the World Allergy Organization Anaphylaxis Guidance 2020, applicable globally across nearly 100 countries, advocate for adjusting dosages based on safety and practicality for emergency preparation and administration. Additionally, these guidelines advise administering 0.3 mg of epinephrine intramuscularly to children aged 6 to 12 years for their safety and effectiveness.

Breakup by Application:

  • Under 6 Years
  • 6 to 12 Years
  • Over 12 Years

6 to 12 years represented the largest segment

Epinephrine autoinjectors are typically prescribed for individuals who have been diagnosed with severe allergies, particularly those at risk of anaphylaxis, which can occur in response to allergens like certain foods, insect stings, or medications. Children aged 6 to 12 years may require an Epinephrine Autoinjector (EAI) due to increasing independence and exposure to allergens outside of parental supervision, such as during school activities, playdates, or meals away from home. This age group is also more prone to severe allergic reactions, making it crucial for them to have immediate access to potentially life-saving treatment in case of anaphylaxis.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

According to the report, hospitals represented the largest segment

The epinephrine autoinjector market report has provided a detailed breakup and analysis of the epinephrine autoinjector market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals hold the largest end-user share in the epinephrine autoinjector market primarily because they are key facilities where severe allergic reactions, or anaphylaxis, are treated. Hospitals regularly stock epinephrine autoinjectors for use in emergency departments, outpatient clinics, and during inpatient stays. They ensure immediate access to life-saving treatment for patients experiencing severe allergic reactions, which can occur unpredictably and require prompt intervention. Additionally, hospitals provide training to healthcare professionals and caregivers on the proper administration of epinephrine, reinforcing their critical role in managing anaphylaxis cases effectively.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America was the largest market for epinephrine autoinjectors

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for epinephrine autoinjectors.

Some of the factors driving the North America epinephrine autoinjector market included the rising prevalence of allergies, increasing awareness about anaphylaxis, and the availability of cost-effective generic versions of autoinjectors. According to the National Library of Medicine, an article published in 2021 in PubMed, between 1.6% and 5.1% of U.S. citizens annually experienced anaphylaxis or suffered from this condition. Also, according to the Asthma and Allergy Foundation of America, in March 2022, about 7.7% of adults and 7.2% of children were diagnosed with seasonal allergic rhinitis. The growing need for epinephrine autoinjectors for quick emergency response is a major factor propelling the expansion of the epinephrine autoinjector industry in the region.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global epinephrine autoinjector market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered are listed below:

  • Adamis Pharmaceuticals Corporation
  • Amneal Pharmaceuticals Inc.
  • Antares Pharma Inc
  • Bausch Health
  • Kaleo Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global epinephrine autoinjector market performed so far, and how will it perform in the coming years ?
  • What are the drivers, restraints, and opportunities in the global epinephrine autoinjector market ?
  • What is the impact of each driver, restraint, and opportunity on the global epinephrine autoinjector market ?
  • What are the key regional markets ?
  • Which countries represent the most attractive epinephrine autoinjector markets ?
  • What is the breakup of the market based on the dosage ?
  • Which is the most attractive dosage in the epinephrine autoinjector market ?
  • What is the breakup of the market based on the application ?
  • Which is the most attractive application in the epinephrine autoinjector market ?
  • What is the breakup of the market based on the end user ?
  • Which is the most attractive end user in the epinephrine autoinjector market ?
  • What is the competitive structure of the global epinephrine autoinjector market ?
  • Who are the key players/companies in the global epinephrine autoinjector market ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Epinephrine Autoinjector Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Dosage

  • 6.1 0.15mg Epinephrine Autoinjector
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 0.3mg Epinephrine Autoinjector
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 0.5mg Epinephrine Autoinjector
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Under 6 Years
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 6 to 12 Years
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Over 12 Years
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adamis Pharmaceuticals Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Antares Pharma Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Bausch Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Kaleo Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Teva Pharmaceutical Industries Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Viatris Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Epinephrine Autoinjector Market: Major Drivers and Challenges
  • Figure 2: Global: Epinephrine Autoinjector Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Epinephrine Autoinjector Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Epinephrine Autoinjector Market: Breakup by Dosage (in %), 2025
  • Figure 5: Global: Epinephrine Autoinjector Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Epinephrine Autoinjector Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Epinephrine Autoinjector Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Epinephrine Autoinjector (0.15mg Epinephrine Autoinjector) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Epinephrine Autoinjector (0.15mg Epinephrine Autoinjector) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Epinephrine Autoinjector (0.3mg Epinephrine Autoinjector) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Epinephrine Autoinjector (0.3mg Epinephrine Autoinjector) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Epinephrine Autoinjector (0.5mg Epinephrine Autoinjector) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Epinephrine Autoinjector (0.5mg Epinephrine Autoinjector) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Epinephrine Autoinjector (Under 6 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Epinephrine Autoinjector (Under 6 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Epinephrine Autoinjector (6 to 12 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Epinephrine Autoinjector (6 to 12 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Epinephrine Autoinjector (Over 12 Years) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Epinephrine Autoinjector (Over 12 Years) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Epinephrine Autoinjector (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Epinephrine Autoinjector (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Epinephrine Autoinjector (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Epinephrine Autoinjector (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Epinephrine Autoinjector (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Epinephrine Autoinjector (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: North America: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: North America: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: United States: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: United States: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Canada: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Canada: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Asia-Pacific: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Asia-Pacific: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: China: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: China: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Japan: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Japan: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: India: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: India: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: South Korea: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: South Korea: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Australia: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Australia: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Indonesia: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Indonesia: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Others: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Others: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Europe: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Europe: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Germany: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Germany: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: France: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: France: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: United Kingdom: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: United Kingdom: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Italy: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Italy: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Spain: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Spain: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Russia: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Russia: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Others: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Others: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Latin America: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Latin America: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Brazil: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Brazil: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Mexico: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Mexico: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Middle East and Africa: Epinephrine Autoinjector Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Middle East and Africa: Epinephrine Autoinjector Market: Breakup by Country (in %), 2025
  • Figure 74: Middle East and Africa: Epinephrine Autoinjector Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Global: Epinephrine Autoinjector Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Epinephrine Autoinjector Industry: Value Chain Analysis
  • Figure 77: Global: Epinephrine Autoinjector Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Epinephrine Autoinjector Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Epinephrine Autoinjector Market Forecast: Breakup by Dosage (in Million USD), 2026-2034
  • Table 3: Global: Epinephrine Autoinjector Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Epinephrine Autoinjector Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Epinephrine Autoinjector Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Epinephrine Autoinjector Market: Competitive Structure
  • Table 7: Global: Epinephrine Autoinjector Market: Key Players